GSK 2820151

Drug Profile

GSK 2820151

Alternative Names: GSK2820151

Latest Information Update: 18 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Antineoplastics
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Apr 2016 Phase-I clinical trials in Solid tumours in United Kingdom (PO) (NCT02630251)
  • 18 Dec 2015 GlaxoSmithKline plans a first-in-human phase I trial for Solid tumours (Late-stage disease, Recurrent, Second-line therapy or greater) in USA (PO) (NCT02630251)
  • 30 Nov 2015 Preclinical trials in Solid tumours in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top